A detailed history of Rafferty Asset Management, LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 115,672 shares of SRRK stock, worth $5.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,672
Previous 132,991 13.02%
Holding current value
$5.27 Million
Previous $1.11 Million 16.35%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.63 - $9.71 $132,143 - $168,167
-17,319 Reduced 13.02%
115,672 $926,000
Q2 2024

Aug 13, 2024

SELL
$7.84 - $16.79 $1.67 Million - $3.57 Million
-212,771 Reduced 61.54%
132,991 $1.11 Million
Q1 2024

May 13, 2024

BUY
$13.2 - $17.76 $3.14 Million - $4.23 Million
238,053 Added 221.01%
345,762 $6.14 Million
Q4 2023

Feb 13, 2024

BUY
$6.52 - $20.32 $702,262 - $2.19 Million
107,709 New
107,709 $2.02 Million
Q2 2022

Aug 12, 2022

SELL
$4.66 - $13.96 $370,591 - $1.11 Million
-79,526 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$11.89 - $24.68 $154,320 - $320,321
12,979 Added 19.5%
79,526 $1.03 Million
Q4 2021

Feb 10, 2022

BUY
$24.14 - $35.18 $708,002 - $1.03 Million
29,329 Added 78.8%
66,547 $1.65 Million
Q3 2021

Nov 10, 2021

SELL
$27.38 - $42.21 $911,781 - $1.41 Million
-33,301 Reduced 47.22%
37,218 $1.23 Million
Q2 2021

Aug 10, 2021

BUY
$26.34 - $46.62 $574,870 - $1.02 Million
21,825 Added 44.82%
70,519 $2.04 Million
Q1 2021

May 10, 2021

BUY
$45.96 - $68.02 $2.24 Million - $3.31 Million
48,694 New
48,694 $2.47 Million

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.35B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.